Arbutus Biopharma (ABUS) Current Deferred Tax Assets (2013 - 2014)
Arbutus Biopharma's (ABUS) quarterly Current Deferred Tax Assets came in at $57000.0 in Q2 2014, down 48.65% quarter-over-quarter from $111000.0 in Q1 2014.
Arbutus Biopharma (ABUS) Current Deferred Tax Assets (2013 - 2014) Analysis & Trends
Arbutus Biopharma has disclosed Current Deferred Tax Assets across 2 years of filings, most recently posting $57000.0 for Q2 2014.
- Current Deferred Tax Assets for Q2 2014 came in at $57000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2014 was $57000.0 (changed N/A YoY), and the FY2013 annual result was $173000.0, changed N/A from the prior year.
- Current Deferred Tax Assets came in at $57000.0 for Q2 2014 at Arbutus Biopharma, down from $111000.0 in the prior quarter.
- In the past five years, Current Deferred Tax Assets ranged from a high of $173000.0 in Q4 2013 to a low of $57000.0 in Q2 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arbutus Biopharma | 882.62 Mn | 882.62 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 57,000.00 |
| Jun 30, 2014 | 57,000.00 |
| Mar 31, 2014 | 111,000.00 |
| Mar 31, 2014 | 111,000.00 |
| Dec 31, 2013 | 173,000.00 |
| Dec 31, 2013 | 173,000.00 |